Intravacc RSV vaccine candidate posts phase I trial results

By The Science Advisory Board staff writers

August 18, 2020 -- Intravacc released results of a clinical phase I trial evaluating its live attenuated respiratory syncytial virus (RSV) vaccine candidate.

In the trial, the vaccine was administered nasally to healthy adult volunteers to assess safety, tolerability, excretion, and immunogenicity. In preclinical studies, the vaccine showed decreased host cell binding and infectivity. The candidate also protected against replication of wild-type RSV in animal models.

The RSV vaccine live attenuated candidate lacks the G-protein but is still able to produce an effective immune response. It was engineered using reverse genetics to remove the attachment protein from the RSV genome.

RSV is a major cause of lower respiratory tract infections in children and the elderly. The virus accounts for approximately 3.2 million hospital admissions per year worldwide and is a leading cause of death in an estimated 120,000 children under the age of five. A pediatric vaccine against RSV would prevent morbidity and mortality in infants and reduce transmission to the elderly.

Intravacc, Celonic to jointly develop COVID-19 vaccine
Vaccine development firm Intravacc and biopharmaceutical contract development and manufacturing organization Celonic are teaming up to develop a COVID-19...
Intravacc, Leiden University explore vaccine quality control without animals
Intravacc has collaborated with the Leiden Academic Center for Drug Research at Leiden University to find alternatives to the use of lab animals in vaccine...
Intravacc, CimCure partner on cancer, COVID-19 vaccines
Intravacc has entered a strategic partnership with CimCure for in-licensing of CimCure's iBoost technology for cancer immunotherapy vaccines and a COVID-19...
Computer tools shorten development time for SARS-CoV-2 drugs
Computer-based tools are helping researchers find potentially promising candidates for vaccines and treatments for SARS-CoV-2 -- and much more quickly...
Intravacc, Versatope to develop universal flu vaccine
Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter